CAR-T-OPENIA: Chimeric Antigen Receptor T-cell Therapy-associated Cytopenias

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35844301

Authors

Alankrita Taneja

Tania Jain

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T-cell is the most recent version in the evolution of cellular therapy with promising responses, which has revolutionized the management of some hematological malignancies in the current times. As the clinical use has progressed rather rapidly since the first approval in 2017, toxicities beyond cytokine release syndrome and immune effector cell-associated neurological syndrome have surfaced. Cytopenias are common in <30 days ("early"), 30-90 days ("short-term") as well as >90 days ("prolonged"); and have clinical implications to patient care as well as resource utilization. We review the details of etiology, factors associated with cytopenias, and management considerations for patients with cytopenias for each of these time-frames. This would potentially serve as a clinical guide for hematological toxicity or CAR-T-OPENIA, which is commonly encountered with the use of CAR T-cell therapy.

Citing Articles

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.

Yang Y, Peng H, Wang J, Li F Exp Hematol Oncol. 2024; 13(1):110.

PMID: 39521987 PMC: 11549815. DOI: 10.1186/s40164-024-00573-9.

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X Nat Commun. 2024; 15(1):3371.

PMID: 38643278 PMC: 11032309. DOI: 10.1038/s41467-024-47801-8.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.

Strati P, Li X, Deng Q, Marques-Piubelli M, Henderson J, Watson G Cell Rep Med. 2023; 4(8):101158.

PMID: 37586321 PMC: 10439270. DOI: 10.1016/j.xcrm.2023.101158.

Single-cell genomics in acquired bone marrow failure syndromes.

Wu Z, Young N Blood. 2023; 142(14):1193-1207.

PMID: 37478398 PMC: 10644099. DOI: 10.1182/blood.2022018581.

Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.

Epperly R, Giordani V, Mikkilineni L, Shah N Hematol Oncol Clin North Am. 2023; 37(6):1169-1188.

PMID: 37349152 PMC: 10592597. DOI: 10.1016/j.hoc.2023.05.010.

References

Burstein D, Maude S, Grupp S, Griffis H, Rossano J, Lin K . Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transplant. 2018; 24(8):1590-1595. DOI: 10.1016/j.bbmt.2018.05.014. View

Brentjens R, Riviere I, Park J, Davila M, Wang X, Stefanski J . Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18):4817-28. PMC: 3208293. DOI: 10.1182/blood-2011-04-348540. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

Lichtenstein D, Schischlik F, Shao L, Steinberg S, Yates B, Wang H . Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021; 138(24):2469-2484. PMC: 8832442. DOI: 10.1182/blood.2021011898. View

Gaut D, Tang K, Sim M, Duong T, Young P, Sasine J . Filgrastim associations with CAR T-cell therapy. Int J Cancer. 2020; 148(5):1192-1196. PMC: 7894177. DOI: 10.1002/ijc.33356. View

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T . Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787. PMC: 7422135. DOI: 10.1182/bloodadvances.2020002509. View

Baur R, Jitschin R, Kharboutli S, Stoll A, Volkl S, Buttner-Herold M . Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report. J Immunother Cancer. 2021; 9(7). PMC: 8287610. DOI: 10.1136/jitc-2021-002721. View

Gutgarts V, Jain T, Zheng J, Maloy M, Ruiz J, Pennisi M . Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biol Blood Marrow Transplant. 2020; 26(6):1071-1076. PMC: 8375362. DOI: 10.1016/j.bbmt.2020.02.012. View

Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F . Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2017; 15(1):47-62. PMC: 6733403. DOI: 10.1038/nrclinonc.2017.148. View

10.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

11.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

12.

Jain T, Litzow M . No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018; 2(22):3393-3403. PMC: 6258912. DOI: 10.1182/bloodadvances.2018020198. View

13.

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

14.

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

15.

Morales-Mantilla D, King K . The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease. Curr Stem Cell Rep. 2018; 4(3):264-271. PMC: 6096761. DOI: 10.1007/s40778-018-0139-3. View

16.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

17.

Jain T, Sauter C, Shah G, Maloy M, Chan J, Scordo M . Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. Leukemia. 2019; 33(10):2540-2544. PMC: 8224498. DOI: 10.1038/s41375-019-0476-y. View

18.

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

19.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

20.

Alvi R, Frigault M, Fradley M, Jain M, Mahmood S, Awadalla M . Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019; 74(25):3099-3108. PMC: 6938409. DOI: 10.1016/j.jacc.2019.10.038. View